First Trust Exchange-Traded Fund III First Trust SMID Growth Strength ETF FSGS 深 沪
等待开盘 12-29 09:30:00 美东时间
31.0514
-0.009
-0.03%
华盛通- 最 高31.0514
- 今 开31.06
- 成交量 86股
- 最 低 31.0514
- 昨 收 31.06
- 总市值 3105.14万
- 52周最高 31.8604
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 24.39
- 委 比 -60.00%
- 总股本 100.00万
- 历史最高 32.5669
- 量 比 0.07
- 振 幅 0.00%
- 历史最低 9.9631
- 每 手 1
- 风险率 1.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
12-25 15:40
BioMarin Boosts Rare Disease Portfolio With Amicus Buyout, Stocks Rally
BioMarin acquires Amicus for $4.8B, expanding its rare disease portfolio with Fabry and Pompe therapies, in a deal expected to close Q2 2026.
12-20 00:07
BioMarin To Acquire Amicus For $14.50/Shr In All-Cash Transaction For Total Equity Value Of ~$4.8B
BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with $599 Million in
12-19 20:48
Akebia Therapeutics Establishes Rare Kidney Disease Pipeline With AKB-097 Acquisition From Q32 Bio And Praliciguat Candidate
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 BioPhase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indicationsPhase 2 trial
12-01 20:09
Processa Pharma's Abstract, "Adaptive Phase 2/3 Study For PCS499 (499) In Patients With Focal Segmental Glomerulosclerosis (FSGS)", Accepted For Presentation At ASN Kidney Week 2025
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and innovative treatments for rare diseases, today announced that its
11-05 22:16
Travere Therapeutics To Present 11 Abstracts, Including A Late-Breaking Poster At American Society Of Nephrology Kidney Week 2025 In Houston, TX November 6-9 Highlights Including Data Duplex Study Showing More Filspari-Treated Patients Achieved Proteinuria Below 0.7 G/g Compared With Irbesartan, Indicating Reduced Kidney Failure Risk In FSGS
Late-breaking poster from DUPLEX Study shows more FILSPARI® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan, correlating with reduced kidney failure risk in FSGSData
10-17 21:09
Travere Shares Are Trading Higher Wednesday: What's Going On?
Travere Therapeutics, Inc. (NASDAQ:TVTX) shares are trading higher on Wednesday...
09-11 03:52
Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026
Travere Therapeutics, Inc., (NASDAQ:TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for
09-10 19:03
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
08-29 00:40
Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings)
6 analysts have shared their evaluations of Travere Therapeutics (NASDAQ:TVTX) ...
08-28 20:00
